作者
Victor Razuk, Anton Camaj, Davide Cao, Johny Nicolas, Christian Hengstenberg, Samantha Sartori, Zhongjie Zhang, David Power, Frans Beerkens, Mauro Chiarito, Nicolas Meneveau, Christophe Tron, Nicolas Dumonteil, Julian D Widder, Markus Ferrari, Roberto Violini, Pieter R Stella, Raban Jeger, Prodromos Anthopoulos, Roxana Mehran, George D Dangas
发表日期
2021/11/15
期刊
Catheterization and Cardiovascular Interventions
卷号
98
期号
6
页码范围
E870-E880
出版商
John Wiley & Sons, Inc.
简介
Objectives
To determine the prognostic impact of anemia in patients randomized to bivalirudin or unfractionated heparin (UFH) during transcatheter aortic valve replacement (TAVR).
Background
Whether the periprocedural use of bivalirudin as compared with UFH in anemic patients undergoing TAVR has an impact on outcomes remains unknown.
Methods
The BRAVO‐3 trial compared the use of bivalirudin versus UFH in 802 high risk patients undergoing transfemoral TAVR for severe symptomatic aortic stenosis. Patients were stratified according to the presence (defined as hemoglobin levels <13 g/dl in men and <12 g/dl in women) or absence of anemia. The primary outcomes were net adverse cardiac events (NACE; a composite of all‐cause mortality, myocardial infarction, stroke, or bleeding) and major bleeding (Bleeding Academic Research Consortium ≥3b) at 30 days.
Results
Among 798 patients …
学术搜索中的文章
V Razuk, A Camaj, D Cao, J Nicolas, C Hengstenberg… - Catheterization and Cardiovascular Interventions, 2021